RxDoctor Payments Data

Phebe Golden, NP

Acute Care · Pueblo, CONPI 1023605706

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 57 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 13 manufacturers reported payments, led by Boston Scientific at 43.4% of the total. Reporting peaked in 2023 at $652 and has fallen 82.0% since, to $118 in 2025.

$1,488in general payments, 2019–2025

Across 57 payments — averaging $26.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$646
  • Medtronic$185
  • Novartis$135
  • Philips North America LLC$117
  • Alnylam Pharmaceuticals Inc.$102
  • Merck$64
  • plus $238 from 7 others

What the payments were for

  • Food & beverage$1,488100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,488 in reported general payments places this provider in the 80th percentile of 239 acute care providers in Colorado.

See all acute care providers in Colorado

Medicare billing

Part B allowed, 2024
$19,195
Medicare patients
137
Services billed
174

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban137$144,306
XareltoRivaroxaban27$42,980
EntrestoSacubitril/Valsartan11$23,828
Flecainide Acetate76$5,881
PradaxaDabigatran Etexilate Mesylate12$3,560
Metoprolol Succinate113$1,595
Verapamil ErVerapamil Hcl13$788
Diltiazem 24hr Er (Cd)Diltiazem Hcl27$770
Amiodarone Hcl25$470
SotalolSotalol Hcl13$428
Carvedilol48$377
Losartan Potassium28$355
Spironolactone30$292
Lisinopril27$228
Metoprolol Tartrate11$155

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$30$42,98027 claims
NovartisEntresto$135$23,82811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 239 acute care providers in Colorado.

Other acute care in Pueblo

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →